Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J2543
1.125 GM
Medicare payment limit per unit (Q4 2026): $1.183
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| Practitioner services (professional claims) | 16 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| Facility outpatient hospital services | 20 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| DME supplier services | 0Not reportable in this setting | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. |
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$1.183per 1.125 GM
Effective Oct 1, 2026 – Dec 31, 2026 · ASP methodology (per CMS file) · based on Q2 2026 ASP data · coinsurance 20.000%
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $1.183 | 1.125 GM | 20% | −2.9% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $1.218 | 1.125 GM | 20% | +12.3% |
Medicare hospital outpatient (OPPS) · Q4 2026
N Packaged: no separate payment
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 81284-0151-10 | Piperacillin Sodium-Tazobactam SodiumApollo Pharmaceuticals | 1 × 10 | 2 | 20 | $23.66 | ASP | Q3 2023 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 81284-0152-10 | Piperacillin Sodium-Tazobactam SodiumApollo Pharmaceuticals | 1 × 10 | 3 | 30 | $35.49 | ASP | Q3 2023 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 81284-0153-10 | Piperacillin Sodium/Tazobactam SodiumApollo Pharmaceuticals | 1 × 10 | 4 | 40 | $47.32 | ASP | Q1 2023 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 81284-0154-01 | Piperacillin Sodium-Tazobactam SodiumApollo Pharmaceuticals | 1 × 1 | 12 | 12 | $14.20 | ASP | Q3 2024 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 81284-0155-01 | Piperacillin Sodium-Tazobactam SodiumApollo Pharmaceuticals | 1 × 1 | 36 | 36 | $42.59 | ASP | Q1 2023 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 61990-0110-02 | Piperacillin Sodium-Tazobactam SodiumApollo Pharmaceuticals Inc. | 1 × 10 | 2 | 20 | $23.66 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 61990-0120-02 | Piperacillin Sodium-Tazobactam SodiumApollo Pharmaceuticals Inc. | 1 × 10 | 3 | 30 | $35.49 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 61990-0130-02 | Piperacillin Sodium-Tazobactam SodiumApollo Pharmaceuticals Inc. | 1 × 10 | 4 | 40 | $47.32 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 61990-0150-01 | Piperacillin Sodium-Tazobactam SodiumApollo Pharmaceuticals Inc. | 1 × 1 | 36 | 36 | $42.59 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 60505-6156-04 | Piperacillin Sodium-Tazobactam SodiumApotex Corp | 1 × 10 | 2 | 20 | $23.66 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 60505-6157-04 | Piperacillin Sodium-Tazobactam SodiumApotex Corp | 1 × 10 | 3 | 30 | $35.49 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 60505-6159-04 | Piperacillin Sodium-Tazobactam SodiumApotex Corp | 1 × 10 | 4 | 40 | $47.32 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 60505-6262-00 | Piperacillin Sodium-Tazobactam SodiumApotex Corp | 1 × 1 | 36 | 36 | $42.59 | ASP | Q2 2024 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 72485-0403-10 | Piperacillin Sodium-Tazobactam SodiumArmas Pharmaceuticals Inc. | 1 × 10 | 3 | 30 | $35.49 | ASP | Q4 2023 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 72485-0404-10 | Piperacillin Sodium-Tazobactam SodiumArmas Pharmaceuticals Inc. | 1 × 10 | 4 | 40 | $47.32 | ASP | Q4 2023 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 70860-0120-20 | Piperacillin Sodium-Tazobactam SodiumAthenex Pharmaceutical Division, LLC | 1 × 10 | 2 | 20 | $23.66 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 70860-0121-30 | Piperacillin Sodium-Tazobactam SodiumAthenex Pharmaceutical Division, LLC | 1 × 10 | 3 | 30 | $35.49 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 70860-0122-50 | Piperacillin Sodium-Tazobactam SodiumAthenex Pharmaceutical Division, LLC | 1 × 10 | 4 | 40 | $47.32 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 70860-0123-99 | Piperacillin Sodium-Tazobactam SodiumAthenex Pharmaceutical Division, LLC | 1 × 1 | 36 | 36 | $42.59 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 83634-0106-50 | Piperacillin Sodium-Tazobactam SodiumAvenacy Inc. | 1 × 10 | 4 | 40 | $47.32 | ASP | Q4 2025 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 00264-3446-11 | Piperacillin Sodium-Tazobactam SodiumB. Braun Medical Inc. | 1 × 24 | 2 | 48 | $56.78 | ASP | Q2 2026 – Q4 2026 | ListedPiperacillin and Tazobactam and Sodium Chloride |
| 00264-3448-11 | Piperacillin Sodium-Tazobactam SodiumB. Braun Medical Inc. | 1 × 24 | 3 | 72 | $85.18 | ASP | Q2 2026 – Q4 2026 | ListedPiperacillin and Tazobactam and Sodium Chloride |
| 00264-3450-22 | Piperacillin Sodium-Tazobactam SodiumB. Braun Medical Inc. | 1 × 24 | 4 | 96 | $113.57 | ASP | Q1 2026 – Q4 2026 | ListedPiperacillin and Tazobactam and Sodium Chloride |
| 00338-9632-24 | ZosynBaxter Healthcare Corporation | 1 × 24 | 2 | 48 | $56.78 | ASP | Q1 2024 – Q4 2026 | ListedZosyn |
| 00338-9636-24 | ZosynBaxter Healthcare Corporation | 1 × 24 | 3 | 72 | $85.18 | ASP | Q1 2024 – Q4 2026 | ListedZosyn |
| 00338-9638-12 | ZosynBaxter Healthcare Corporation | 1 × 12 | 4 | 48 | $56.78 | ASP | Q1 2024 – Q4 2026 | ListedZosyn |
| 68001-0506-30 | Piperacillin Sodium-Tazobactam SodiumBluePoint Laboratories | 1 × 10 | 2 | 20 | $23.66 | ASP | Q1 2024 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 68001-0507-82 | Piperacillin Sodium-Tazobactam SodiumBluePoint Laboratories | 1 × 10 | 3 | 30 | $35.49 | ASP | Q1 2024 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 68001-0508-31 | Piperacillin Sodium-Tazobactam SodiumBluePoint Laboratories | 1 × 10 | 4 | 40 | $47.32 | ASP | Q1 2024 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 72572-0414-10 | Piperacillin Sodium-Tazobactam SodiumCivica, Inc. | 1 × 10 | 3 | 30 | $35.49 | ASP | Q2 2026 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 72572-0418-10 | Piperacillin Sodium-Tazobactam SodiumCivica, Inc. | 1 × 10 | 4 | 40 | $47.32 | ASP | Q2 2026 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 72572-0573-10 | Piperacillin Sodium-Tazobactam SodiumCivica, Inc. | 1 × 10 | 3 | 30 | $35.49 | ASP | Q3 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 72572-0574-10 | Piperacillin Sodium-Tazobactam SodiumCivica, Inc. | 1 × 10 | 4 | 40 | $47.32 | ASP | Q3 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 55150-0119-30 | Piperacillin Sodium-Tazobactam SodiumEugia US LLC | 1 × 10 | 2 | 20 | $23.66 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 55150-0120-30 | Piperacillin Sodium-Tazobactam SodiumEugia US LLC | 1 × 10 | 3 | 30 | $35.49 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 55150-0121-50 | Piperacillin Sodium-Tazobactam SodiumEugia US LLC | 1 × 10 | 4 | 40 | $47.32 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 63323-0981-21 | Piperacillin Sodium-Tazobactam SodiumFreseniUS Kabi USA, LLC | 1 × 10 | 2 | 20 | $23.66 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 63323-0981-53 | Piperacillin Sodium-Tazobactam SodiumFreseniUS Kabi USA, LLC | 1 × 10 | 2 | 20 | $23.66 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 63323-0983-21 | Piperacillin Sodium-Tazobactam SodiumFreseniUS Kabi USA, LLC | 1 × 10 | 3 | 30 | $35.49 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 63323-0983-53 | Piperacillin Sodium-Tazobactam SodiumFreseniUS Kabi USA, LLC | 1 × 10 | 3 | 30 | $35.49 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 65219-0256-00 | Piperacillin Sodium-Tazobactam SodiumFreseniUS Kabi USA, LLC | 1 × 1 | 36 | 36 | $42.59 | ASP | Q4 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 65219-0256-24 | Piperacillin Sodium-Tazobactam SodiumFreseniUS Kabi USA, LLC | 1 × 1 | 36 | 36 | $42.59 | ASP | Q4 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 65219-0256-28 | Piperacillin Sodium-Tazobactam SodiumFreseniUS Kabi USA, LLC | 1 × 1 | 36 | 36 | $42.59 | ASP | Q2 2022 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 65219-0259-45 | Piperacillin Sodium-Tazobactam SodiumFreseniUS Kabi USA, LLC | 1 × 10 | 4 | 40 | $47.32 | ASP | Q1 2022 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 65219-0259-55 | Piperacillin Sodium-Tazobactam SodiumFreseniUS Kabi USA, LLC | 1 × 10 | 4 | 40 | $47.32 | ASP | Q1 2022 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 65219-0434-20 | Piperacillin Sodium-Tazobactam SodiumFreseniUS Kabi USA, LLC | 1 × 10 | 2 | 20 | $23.66 | ASP | Q2 2024 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 65219-0436-20 | Piperacillin Sodium-Tazobactam SodiumFreseniUS Kabi USA, LLC | 1 × 10 | 3 | 30 | $35.49 | ASP | Q2 2024 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 00409-2999-14 | Piperacillin Sodium-Tazobactam SodiumPfizer Inc | 1 × 1 | 12 | 12 | $14.20 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 00409-3374-02 | Piperacillin Sodium-Tazobactam SodiumPfizer Inc | 1 × 10 | 2 | 20 | $23.66 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 00409-3378-13 | Piperacillin Sodium-Tazobactam SodiumPfizer Inc | 1 × 10 | 3 | 30 | $35.49 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 00409-3379-04 | Piperacillin Sodium-Tazobactam SodiumPfizer Inc | 1 × 10 | 4 | 40 | $47.32 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 00409-3383-02 | Piperacillin Sodium-Tazobactam SodiumPfizer Inc | 1 × 10 | 2 | 20 | $23.66 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 00409-3383-10 | Piperacillin Sodium-Tazobactam SodiumPfizer Inc | 1 × 10 | 2 | 20 | $23.66 | ASP | Q1 2026 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 00409-3385-13 | Piperacillin Sodium-Tazobactam SodiumPfizer Inc | 1 × 10 | 3 | 30 | $35.49 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 00409-3385-15 | Piperacillin Sodium-Tazobactam SodiumPfizer Inc | 1 × 10 | 3 | 30 | $35.49 | ASP | Q1 2026 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 00409-3390-04 | Piperacillin Sodium-Tazobactam SodiumPfizer Inc | 1 × 10 | 4 | 40 | $47.32 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 00409-3390-10 | Piperacillin And TazobactamPfizer Inc | 1 × 10 | 4 | 40 | $47.32 | ASP | Q4 2025 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 66794-0216-41 | Piperacillin Sodium-Tazobactam SodiumPiramal Critical Care Inc | 1 × 10 | 2 | 20 | $23.66 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 66794-0217-41 | Piperacillin Sodium-Tazobactam SodiumPiramal Critical Care Inc | 1 × 10 | 3 | 30 | $35.49 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 66794-0218-41 | Piperacillin Sodium-Tazobactam SodiumPiramal Critical Care Inc | 1 × 10 | 4 | 40 | $47.32 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 25021-0164-30 | Piperacillin Sodium-Tazobactam SodiumSagent Pharmaceuticals | 1 × 10 | 2 | 20 | $23.66 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin, Tazobactam |
| 25021-0165-30 | Piperacillin Sodium-Tazobactam SodiumSagent Pharmaceuticals | 1 × 10 | 3 | 30 | $35.49 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin, Tazobactam |
| 25021-0166-48 | Piperacillin Sodium-Tazobactam SodiumSagent Pharmaceuticals | 1 × 10 | 4 | 40 | $47.32 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin, Tazobactam |
| 25021-0181-99 | Piperacillin Sodium-Tazobactam SodiumSagent Pharmaceuticals | 1 × 1 | 36 | 36 | $42.59 | ASP | Q1 2022 – Q4 2026 | ListedPiperacillin, Tazobactam |
| 00781-3110-95 | Piperacillin Sodium-Tazobactam SodiumSandoz Inc. | 1 × 10 | 2 | 20 | $23.66 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 00781-3113-95 | Piperacillin Sodium-Tazobactam SodiumSandoz Inc. | 1 × 10 | 3 | 30 | $35.49 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 00781-3114-95 | Piperacillin Sodium-Tazobactam SodiumSandoz Inc. | 1 × 10 | 4 | 40 | $47.32 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 00781-3180-94 | Piperacillin Sodium-Tazobactam SodiumSandoz Inc. | 1 × 1 | 36 | 36 | $42.59 | ASP | Q4 2022 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 00781-9210-95 | Piperacillin Sodium-Tazobactam SodiumSandoz Inc. | 1 × 10 | 2 | 20 | $23.66 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 00781-9213-95 | Piperacillin Sodium-Tazobactam SodiumSandoz Inc. | 1 × 10 | 3 | 30 | $35.49 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 00781-9214-95 | Piperacillin Sodium-Tazobactam SodiumSandoz Inc. | 1 × 10 | 4 | 40 | $47.32 | ASP | Q1 2021 – Q4 2026 | Excluded listingPiperacillin and Tazobactam |
| 44567-0801-10 | Piperacillin Sodium-Tazobactam SodiumWG Critical Care, LLC | 1 × 10 | 2 | 20 | $23.66 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 44567-0802-10 | Piperacillin Sodium-Tazobactam SodiumWG Critical Care, LLC | 1 × 10 | 3 | 30 | $35.49 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 44567-0803-10 | Piperacillin Sodium-Tazobactam SodiumWG Critical Care, LLC | 1 × 10 | 4 | 40 | $47.32 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
| 44567-0804-01 | Piperacillin Sodium-Tazobactam SodiumWG Critical Care, LLC | 1 × 1 | 36 | 36 | $42.59 | ASP | Q1 2021 – Q4 2026 | ListedPiperacillin and Tazobactam |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 61990-0140-01 | Piperacillin Sodium-Tazobactam SodiumAPOLLO PHARMACEUTICALS USA INC. | 1 × 1 | 12 | 12 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 2000 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| CMS Policy |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
| — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $1.085 | 1.125 GM | 20% | −0.5% | — |
|---|
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $1.091 | 1.125 GM | 20% | +1.9% | — |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $1.071 | 1.125 GM | 20% | −3.3% | — |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $1.108 | 1.125 GM | 20% | −1.0% | — |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $1.119 | 1.125 GM | 20% | −1.4% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $1.135 | 1.125 GM | 20% | +3.0% | — |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $1.102 | 1.125 GM | 20% | −6.6% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $1.180 | 1.125 GM | 20% | +12.4% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $1.050 | 1.125 GM | 20% | −10.8% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $1.177 | 1.125 GM | 20% | +32.8% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $0.886 | 1.125 GM | 20% | −34.8% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $1.359 | 1.125 GM | 20% | +1.7% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $1.336 | 1.125 GM | 20% | −12.3% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $1.523 | 1.125 GM | — | +3.0% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $1.479 | 1.125 GM | — | +15.2% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $1.284 | 1.125 GM | — | −5.0% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $1.352 | 1.125 GM | — | −4.5% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $1.416 | 1.125 GM | — | −4.1% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $1.477 | 1.125 GM | — | +4.2% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $1.418 | 1.125 GM | — | −6.0% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $1.508 | 1.125 GM | — | −6.4% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $1.611 | 1.125 GM | — | — | — |
|---|
| 00206-8860-02 | Piperacillin Sodium-Tazobactam SodiumBAXTER | 50 × 24 | 2 | 48 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | ListedZosyn in Galaxy Containers |
|---|
| 00206-8861-02 | Piperacillin Sodium-Tazobactam SodiumBAXTER | 50 × 24 | 3 | 72 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | ListedZosyn in Galaxy Containers |
|---|
| 00206-8862-02 | Piperacillin Sodium-Tazobactam SodiumBAXTER | 100 × 12 | 4 | 48 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | ListedZosyn in Galaxy Containers |
|---|
| 72572-0576-10 | Piperacillin Sodium-Tazobactam SodiumCivica, Inc. | 1 × 10 | 3 | 30 | ASP | Q4 2022 – Q1 2026Not in Q4 2026 file | Excluded listingPiperacillin and Tazobactam |
|---|
| 72572-0577-10 | Piperacillin Sodium-Tazobactam SodiumCivica, Inc. | 1 × 10 | 4 | 40 | ASP | Q4 2022 – Q1 2026Not in Q4 2026 file | Excluded listingPiperacillin and Tazobactam |
|---|
| 63323-0300-30 | Piperacillin Sodium-Tazobactam SodiumFRESENIUS KABI | 1 × 10 | 3 | 30 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | ListedPiperacillin and Tazobactam |
|---|
| 63323-0300-36 | Piperacillin Sodium-Tazobactam SodiumFRESENIUS KABI | 1 × 10 | 3 | 30 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | ListedPiperacillin and Tazobactam |
|---|
| 63323-0304-74 | Piperacillin Sodium-Tazobactam SodiumFRESENIUS KABI | 1 × 1 | 36 | 36 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | ListedPiperacillin and Tazobactam |
|---|
| 63323-0304-78 | Piperacillin Sodium-Tazobactam SodiumFRESENIUS KABI | 1 × 1 | 36 | 36 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | ListedPiperacillin and Tazobactam |
|---|
| 63323-0304-94 | Piperacillin Sodium-Tazobactam SodiumFRESENIUS KABI | 1 × 1 | 36 | 36 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | ListedPiperacillin and Tazobactam |
|---|
| 63323-0309-20 | PIPERACILLIN AND TAZOBACTAMFRESENIUS KABI | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | ListedPiperacillin and Tazobactam |
|---|
| 63323-0309-26 | Piperacillin Sodium-Tazobactam SodiumFRESENIUS KABI | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q2 2022Not in Q4 2026 file | ListedPiperacillin and Tazobactam |
|---|
| 63323-0320-50 | PIPERACILLIN AND TAZOBACTAMFRESENIUS KABI | 1 × 10 | 4 | 40 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | ListedPiperacillin and Tazobactam |
|---|
| 63323-0320-56 | PIPERACILLIN AND TAZOBACTAMFRESENIUS KABI | 1 × 10 | 4 | 40 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | ListedPiperacillin and Tazobactam |
|---|
| 63323-0982-52 | Piperacillin Sodium-Tazobactam SodiumFRESENIUS KABI | 1 × 10 | 4 | 40 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | ListedPiperacillin and Tazobactam |
|---|
| 63323-0982-54 | Piperacillin Sodium-Tazobactam SodiumFRESENIUS KABI | 1 × 10 | 4 | 40 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | ListedPiperacillin and Tazobactam |
|---|
| 71288-0002-31 | Piperacillin Sodium-Tazobactam SodiumMeitheal Pharmaceuticals Inc. | 1 × 10 | 2 | 20 | ASP | Q3 2023 – Q1 2025Not in Q4 2026 file | Excluded listingPiperacillin and Tazobactam |
|---|
| 71288-0003-31 | Piperacillin Sodium-Tazobactam SodiumMeitheal Pharmaceuticals Inc. | 1 × 10 | 3 | 30 | ASP | Q3 2023 – Q1 2025Not in Q4 2026 file | Excluded listingPiperacillin and Tazobactam |
|---|
| 71288-0004-51 | Piperacillin Sodium-Tazobactam SodiumMeitheal Pharmaceuticals Inc. | 1 × 10 | 4 | 40 | ASP | Q4 2023 – Q1 2025Not in Q4 2026 file | Excluded listingPiperacillin and Tazobactam |
|---|
| 67457-0521-22 | PIPERACILLIN AND TAZOBACTAMMYLAN INSTITUTIONAL LLC | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingPiperacillin and Tazobactam |
|---|
| 67457-0522-37 | Piperacillin Sodium-Tazobactam SodiumMYLAN INSTITUTIONAL LLC | 1 × 10 | 3 | 30 | ASP | Q1 2021 – Q3 2023Not in Q4 2026 file | Excluded listingPiperacillin and Tazobactam |
|---|
| 67457-0523-45 | PIPERACILLIN AND TAZOBACTAMMYLAN INSTITUTIONAL LLC | 1 × 10 | 4 | 40 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingPiperacillin and Tazobactam |
|---|
| 25021-0175-20 | Piperacillin Sodium-Tazobactam SodiumSagent Pharmaceuticals | 1 × 10 | 2 | 20 | ASP | Q2 2023 – Q2 2025Not in Q4 2026 file | Excluded listingPiperacillin, Tazobactam |
|---|
| 25021-0176-20 | Piperacillin Sodium-Tazobactam SodiumSagent Pharmaceuticals | 1 × 10 | 3 | 30 | ASP | Q3 2022 – Q2 2025Not in Q4 2026 file | Excluded listingPiperacillin, Tazobactam |
|---|
| 25021-0177-50 | Piperacillin Sodium-Tazobactam SodiumSagent Pharmaceuticals | 1 × 10 | 4 | 40 | ASP | Q2 2023 – Q2 2025Not in Q4 2026 file | Excluded listingPiperacillin, Tazobactam |
|---|
| 00781-3350-95 | Piperacillin Sodium-Tazobactam SodiumSANDOZ | 1 × 10 | 3 | 30 | ASP | Q1 2021 – Q2 2022Not in Q4 2026 file | Excluded listingPiperacillin and Tazobactam |
|---|
| 00781-3367-95 | PIPERACILLIN SODIUM/ TAZOSANDOZ | 1 × 10 | 4 | 40 | ASP | Q1 2021 – Q2 2022Not in Q4 2026 file | Excluded listingPiperacillin and Tazobactam |
|---|
| 00781-9344-95 | PIPERACILLIN SODIUM/ TAZOSANDOZ | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingPiperacillin and Tazobactam |
|---|
| 00781-9350-95 | PIPERACILLIN SODIUM/ TAZOSANDOZ | 1 × 10 | 3 | 30 | ASP | Q1 2021 – Q2 2022Not in Q4 2026 file | Excluded listingPiperacillin and Tazobactam |
|---|
| 00781-9367-95 | PIPERACILLIN SODIUM/ TAZOSANDOZ | 1 × 10 | 4 | 40 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingPiperacillin and Tazobactam |
|---|
| 39822-0123-02 | PIPERACILLIN AND TAZOBACTAMX-GEN PHARMACEUTICALS INC | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q2 2022Not in Q4 2026 file | Excluded listingPiperacillin, Tazobactam |
|---|
| 39822-0125-04 | PIPERACILLIN AND TAZOBACTAMX-GEN PHARMACEUTICALS INC | 1 × 10 | 3 | 30 | ASP | Q1 2021 – Q2 2022Not in Q4 2026 file | Excluded listingPiperacillin, Tazobactam |
|---|
| 39822-0127-06 | PIPERACILLIN AND TAZOBACTAMX-GEN PHARMACEUTICALS INC | 1 × 10 | 4 | 40 | ASP | Q1 2021 – Q2 2022Not in Q4 2026 file | Excluded listingPiperacillin, Tazobactam |
|---|
| 39822-0139-07 | PIPERACILLIN AND TAZOBACTAMX-GEN PHARMACEUTICALS INC | 1 × 1 | 36 | 36 | ASP | Q1 2021 – Q2 2022Not in Q4 2026 file | Excluded listingPiperacillin, Tazobactam |
|---|
| 70594-0078-02 | Piperacillin Sodium-Tazobactam SodiumXellia Pharmaceuticals USA, LLC. | 1 × 10 | 2 | 20 | ASP | Q3 2022 – Q1 2025Not in Q4 2026 file | Excluded listingPIPERACILLIN SODIUM and TAZOBACTAM SODIUM |
|---|
| 70594-0079-02 | Piperacillin Sodium-Tazobactam SodiumXellia Pharmaceuticals USA, LLC. | 1 × 10 | 3 | 30 | ASP | Q3 2022 – Q1 2025Not in Q4 2026 file | Excluded listingPIPERACILLIN SODIUM and TAZOBACTAM SODIUM |
|---|
| 70594-0080-02 | Piperacillin Sodium-Tazobactam SodiumXellia Pharmaceuticals USA, LLC. | 1 × 10 | 4 | 40 | ASP | Q3 2022 – Q1 2025Not in Q4 2026 file | Excluded listingPIPERACILLIN SODIUM and TAZOBACTAM SODIUM |
|---|